Opsonix is developing and commercializing a pathogen-extracting therapy that uses its proprietary pathogen-capture proteins to remove infectious microbes and the toxins they release from circulating blood, offering a new broad-spectrum approach to transform the treatment of blood-borne infectious diseases, including sepsis.
Opsonix’s pathogen-capture proteins are engineered versions of human opsonins—molecular components of the innate immune system that help to clear our bodies of pathogens and released toxins. Our most advanced pathogen-capture protein, FcMBL, binds all types of microorganisms, including bacteria, fungi, parasites and viruses, as well as many toxins. The pathogen-extracting therapy incorporates FcMBL into an extracorporeal medical device to remove infectious agents from circulating blood in patients with systemic infections that are the cause of sepsis.
Company Details
- Address
- Cambridge, Ma
- Phone
- 617-444-8644
- in****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- opsonixbio.com
- HQ
- Cambridge, MA
Opsonix, Inc. Questions
Opsonix, Inc.'s helpline number is 617-444-8644
Opsonix, Inc.'s website is opsonixbio.com
Opsonix, Inc.'s LinkedIn profile is https://www.linkedin.com/company/opsonix-inc-
Opsonix, Inc.'s industry is
Biotechnology Research
Opsonix, Inc.'s top competitors are
Interius Biotherapeutics,
Headway,
Amplitude Therapeutics,
Avalara,
Lifescience Org,
Alma,
Acrivon Therapeutics, Inc.,
Xione Therapeutics, Inc.,
Rula,
Octave.
Opsonix, Inc.'s support email address is info@opsonixbio.com
Opsonix, Inc.'s categories are Biotechnology Research
